PAPoots
GLP-1 Enthusiast
Eli Lilly's weight loss drug retatrutide clears first late-stage study
KEY POINTS
Eli Lilly said its next-generation obesity drug delivered what appears to be the highest weight loss seen so far in a late-stage trial and reduced knee arthritis pain, clearing the first of several upcoming studies on the weekly injection.
The drugmaker is betting big on the treatment, retatrutide, as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.
Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments.
KEY POINTS
Eli Lilly said its next-generation obesity drug delivered what appears to be the highest weight loss seen so far in a late-stage trial and reduced knee arthritis pain, clearing the first of several upcoming studies on the weekly injection.
The drugmaker is betting big on the treatment, retatrutide, as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.
Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments.
